A Phase 3 interventional study of Enlicitide and Rosuvastatin in Hyperlipidemia, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 87 sites in 11 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Hyperlipidemias.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 2nd largest by enrollment, is one of 2 that started in 2025, is one of 7 in phase 3, and was the 30th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 8 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 996 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 114 across the 30 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C.
The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive enlicitide and a rosuvastatin-matching placebo. Both will be delivered orally once daily (QD) for up to 12 weeks.
Drug: Enlicitide · Drug: Placebo for Rosuvastatin
Participants will receive enlicitide and rosuvastatin. Both will be delivered orally QD for up to 12 weeks.
Drug: Enlicitide · Drug: Rosuvastatin
Participants will receive rosuvastatin and an enlicitide-matching placebo. Both will be delivered orally QD for up to 12 weeks.
Drug: Rosuvastatin · Drug: Placebo for Enlicitide
Participants will receive an enlicitide-matching placebo and a rosuvastatin-matching placebo. Placebos will be delivered orally QD for up to 12 weeks.
Drug: Placebo for Enlicitide · Drug: Placebo for Rosuvastatin
Oral Tablet
Also known as: MK-0616, Enlicitide decanoate
Oral Capsule
Oral Tablet
Oral Capsule
Mean Percent Change from Baseline in LDL-C at Week 8 (Enlicitide + Rosuvastatin Versus Placebo)
Blood samples will be collected at baseline and at Week 8 to assess mean percent change in LDL-C between participants treated with enlicitide and rosuvastatin versus placebo.
Time frame: Baseline and Week 8
Mean Percent Change from Baseline in LDL-C at Week 8
Blood samples will be collected at baseline and at Week 8 to assess mean percent change in LDL-C.
Time frame: Baseline and Week 8
Mean Percent Change from Baseline in Apolipoprotein B (ApoB) at Week 8
Blood samples will be collected at baseline and at Week 8 to assess mean percent change in ApoB.
Time frame: Baseline and Week 8
Number of Participants with One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 20 weeks
Number of Participants who Discontinue Study Drug Due to One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 12 weeks
Mean Percent Change from Baseline in LDL-C at Week 12
Blood samples will be collected at baseline and at Week 12 to assess mean percent change in LDL-C.
Time frame: Baseline and Week 12
Mean Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) at Week 8
Blood samples will be collected at baseline and at Week 8 to assess mean percent change in non-HDL-C.
Time frame: Baseline and Week 8
Percent Change from Baseline in Lipoprotein (a) (Lp[a]) at Week 8
Blood samples will be collected at baseline and at Week 8 to assess percent change in Lp(a).
Time frame: Baseline and Week 8
Percentage of Participants with LDL-C <70 mg/dL and ≥50% Reduction from Baseline at Week 8
Blood samples will be collected at baseline and at Week 8 to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline.
Time frame: Baseline and Week 8
Percentage of Participants with LDL-C <55 mg/dL and ≥50% Reduction from Baseline at Week 8
Blood samples will be collected at baseline and at Week 8 to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline.
Time frame: Baseline and Week 8
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2025 to primary completion in Aug 2026, 8 months.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Enlicitide · Rosuvastatin